USPTO serial 79975813
KLARIFY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 25, 2026
- Examiner
- STRUCK, ROBERT J
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with KLARIFY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Monica Riva Talley
Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C1101 K Street, N.W., 10th FloorWashington, DC 20005United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary preparations for immunotherapeutic purposes for the treatment of autoimmune diseases; pharmaceutical and veterinary preparations for diagnosis, prevention and treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy; diagnostic preparations for medical purposes, diagnostic reagents and diagnostic testing strips for medical use in the field of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy; eye drops; nose drops, nasal sprays for medical purposes; pharmaceutical preparations for inhalers for the treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, and respiratory allergic diseases; pharmaceutical preparations in the form of injectable pharmaceuticals, particularly adrenaline, for treatment of anaphylactic reactions; ; probiotic preparations for medical and veterinary use; infant formula, namely, lactose free infant formula and hydrolyzed milk infant formula; additives for infant formula to prevent the development of allergies, namely, dietary supplements; food for babies; diagnostic testing materials for medical use, namely, diagnostic test patch for application to the skin for determining allergies; allergy and asthma testing kits, namely, diagnostic test patch for application to the skin for determining allergic reactions; none of the aforesaid goods for use in the cardiovascular field nor for use in continence management, but all solely for use in relation to allergy and asthma | ACTIVE | — |
| 009 | computer software, namely downloadable computer software for medical use for assisting allergy and asthma patients and medical personnel in storing and handling patient data; diagnostic apparatus for testing food, namely, for mold detection; optical sensors for detecting and analyzing the presence of chemicals, toxins, mold and allergens in food, food components and food products; downloadable electronic publications in the nature of magazines and periodicals in the field of allergy and asthma; downloadable electronic magazines and periodicals in the field of allergy and asthma; online downloadable electronic questionnaires on medical issues relating to allergy and asthma; none of the aforesaid goods relating to the cardiovascular field nor for use in continence management, but all solely for use in relation to allergy and asthma | ACTIVE | — |
| 016 | Printed matter, namely, printed calendars and forms; printed instructional and teaching materials except apparatus in the field of allergy and asthma; printed magazines and periodicals in the field of allergy and asthma; printed questionnaires on medical issues relating to allergy and asthma; none of the aforesaid goods relating to the cardiovascular field nor for use in continence management, but all solely for use in relation to allergy and asthma | ACTIVE | — |
| 038 | Providing access, with or without subscription, to an e-commerce platform on the Internet giving users access to medical information in the allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic disease as well as atopic dermatitis and food allergy fields, namely, providing access to telecommunication networks; none of the aforesaid services in relation to the cardiovascular field nor in relation to continence management, but all in relation to allergy and asthma only | ACTIVE | — |
| 042 | Scientific, technological, medical, and pharmacological research services and design relating thereto, namely, scientific research and technological research in the field of manufacturing processes, medical research, pharmaceutical research, pharmaceutical products development and new product design; scientific and medical laboratory services; medical and scientific research, namely, conducting clinical trials for others; computer services, namely, the creation of online communities for registered users to participate in discussions, and engage in social networking; providing a website featuring technology that enables consumers to form virtual communities, engage in social networking and share information regarding food, food components, and food products; all of the aforesaid services in relation to allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy; statistical investigations and statistical studies in the fields of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis and food allergy, namely, medical research; none of the aforesaid services in relation to the cardiovascular field nor in relation to continence management, but all in relation to allergy and asthma only | ACTIVE | — |
| 044 | Medical services and medical healthcare services; medical consulting services, namely, counselling and information regarding immunotherapy, allergy, asthma, allergic rhinitis, allergic asthma, respiratory allergic diseases as well as atopic dermatitis, food allergy, and anaphylactic reactions; providing patient support relating to immunotherapy as well as to diagnosing, prevention and treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases, atopic dermatitis, food allergy, and anaphylactic reactions, also electronically or digitally, including through a website with or without subscription, namely, medical consultations; providing medical information to medical professionals relating to immunotherapy as well as to diagnosing, prevention and treatment of allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases, atopic dermatitis, food allergy, and anaphylactic reactions, also electronically or digitally, including through a website; medical diagnostic services, namely, medical diagnostic testing, monitoring and reporting services; all of the aforesaid services in relation to allergy, asthma, allergic rhinitis, allergic asthma, rhinoconjunctivitis, respiratory allergic diseases as well as atopic dermatitis, food allergy, and anaphylactic reactions; none of the aforesaid services in relation to the cardiovascular field nor in relation to continence management, but all in relation to allergy and asthma only | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ALK-Abelló A/S
- Other trademarks owned by ALK-Abelló A/S
- Other trademarks owned by ALK-Abelló A/S
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 016
- Other trademarks in Class 038
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named KLARIFY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 25, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 25, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 5, 2026 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Jun 16, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jun 16, 2025 | OP.N | OPPOSITION NOT INSTITUTED | — |
| Jun 12, 2025 | PCBM | PETITION TO DIRECTOR WITHDRAWN | — |
| Jun 11, 2025 | PETL | COMMUNICATION RECEIVED FROM PETITIONER | — |
| May 31, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| May 29, 2025 | OPPF | OPPOSITION PAPERS RECEIVED AT TTAB | — |
| May 29, 2025 | APET | ASSIGNED TO PETITION STAFF | — |
| May 22, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| May 12, 2025 | OPPF | OPPOSITION PAPERS RECEIVED AT TTAB | — |
| May 12, 2025 | TPDR | TEAS PETITION TO DIRECTOR RECEIVED | — |
| Dec 12, 2024 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Nov 12, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 12, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 1, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 23, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 4, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 29, 2024 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Aug 12, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 17, 2024 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Jun 17, 2024 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Mar 8, 2024 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 21, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 3, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 3, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 8, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 8, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 8, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Aug 1, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 31, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 31, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 21, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 30, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 30, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 1, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 30, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 28, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 5, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 1, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 30, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jul 28, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |